FOAMIX ANNOUNCES RESULTS OF PHASE II/III LICE TREATMENT STUDY

Foamix has announced today the results of its Phase II/III study of one of its lead products, PerFoam, for the treatment of lice. Trial data shows evidence of safety and a 96 percent efficacy rate. Foamix anticipates launching PerFoam in the Israeli market in 2006, and in the global market in 2006/7.

PerFoam, comprised of Permethrin and two proprietary enhancers, is an alcohol-free, non-irritating, drip-free foam for the treatment of head lice. The study was conducted at the Laniado Medical Center, Netanya, Israel.

Preschool and elementary-age children, three-10 years of age, and their families are infested most often from this easily spread condition. Hundreds of millions of cases of louse infestation are reported annually worldwide, with a clear increase over the past few decades. It has been estimated that 10-12 million Americans are infested yearly with lice. Elementary school-age children account for a quarter of this number.